The Recommended Items feature empowers providers to strategically suggest additional, relevant programs to patients at the moment of peak engagement—right after checkout. By surfacing curated follow-up or complementary programs, providers can:   🔼 Increase Revenue per Patient Patients are more likely to enroll in multiple programs when presented with logical next steps immediately after purchase. This feature helps convert…

We’re excited to announce our new Facebook group exclusively for providers—a space to connect, share ideas, marketing tips, and clinical insights that help all of us succeed. What to expect: • Marketing tips to help you grow your practice • Community support and insights from fellow DrWell providers • A place to ask questions, collaborate,…

According to this Medscape article, recent research is shining a spotlight on an unexpected benefit of GLP‑1 receptor agonists (GLP‑1 RAs) weight loss medications: they may help improve chronic inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa (HS), and even wound healing . From Diabetes to Dermatology Originally developed to manage type 2 diabetes, GLP‑1 RAs (e.g., semaglutide,…

The surge in GLP-1 medications like semaglutide and tirzepatide is not only revolutionizing weight management but also reshaping the medical aesthetics industry.   A recent McKinsey study has revealed that 63% of patients pursuing aesthetic treatments after starting GLP-1s had never received any aesthetics procedure before.   These patients are entering the market with fresh…

Legal. Legit. Licensed. If you’re prescribing GLP-1s, make sure you’re doing it legally. At DrWell, were integrated with top-tier licensed 503A and 503B compounding pharmacies-never research-grade sources that could jeopardize your license. Sure, we’ve all received the emails with the great rates on “peptides” and GLP-1s. You may have thought access to some of these…

While coaching her weight management patients, Jennifer “Coop” Cooper, APRN, nurse practitioner in the office of Dr. Jonathan Kaplan, and Chief Nursing Officer at DrWell, noticed patients who switched from semaglutide to tirzepatide had better appetite suppression but an increase in food noise whereas patients on semaglutide had greater food noise reduction but less appetite…